Epitel’s $26M Infusion: A Strategic Play to End the EEG Diagnosis Bottleneck

SALT LAKE CITY, UT – July 28, 2026 – Epitel, Inc., a digital health company at the forefront of brain monitoring, today announced a $26 million Series B funding round. While funding announcements in the health tech space are frequent, this one signals a pivotal shift in a long-stagnant area of diagnostics. Co-led by Catalyst Health Ventures and Genoa Ventures, the capital is not just for growth; it’s a strategic deployment to dismantle the decades-old barriers surrounding neurological care, specifically for the millions affected by seizures.

This move goes beyond simple market expansion for Epitel’s REMI® Remote EEG Monitoring System. It represents a calculated bet on a future where complex neurological diagnostics are no longer confined to specialized hospital wings but are accessible, continuous, and powered by intelligent analysis. For business leaders, investors, and strategists, Epitel's initiative provides a masterclass in how targeted technology—combining wireless wearables, cloud infrastructure, and AI—can address a critical unmet need, creating significant market opportunity while driving health equity.

The Decades-Old Diagnosis Dilemma

To grasp the significance of Epitel’s strategy, one must first understand the problem it aims to solve. The electroencephalogram (EEG), a cornerstone for diagnosing epilepsy and other seizure disorders, has been hampered by logistical and technological constraints for years. Seizures are unpredictable, often occurring without obvious clinical signs. The diagnostic challenge is capturing these fleeting neurological events.

Traditional EEG monitoring typically requires a hospital stay, where patients are tethered to bulky equipment for a maximum of 72 hours. This short window is often insufficient to capture sporadic seizure activity, leading to diagnostic delays that can stretch for months or even years. Furthermore, access is a profound issue. In the United States, where 9.2 million people experience seizures annually, an estimated 40 percent lack access to EEG services. This is largely because only 27 percent of U.S. hospitals have the necessary EEG capacity, creating a severe bottleneck in neurological care, particularly in rural and underserved communities.

"Millions of Americans with suspected seizures still face significant barriers to diagnosis because access to EEG remains limited, particularly outside major medical centers," said Steve Pacelli, President & CEO of Epitel. This access gap isn’t just an inconvenience; it's a critical failure point in the healthcare system that leaves patients in diagnostic limbo and prevents timely, effective treatment.

A Strategic Shift to Wireless, AI-Powered Monitoring

Epitel’s REMI system is engineered to directly confront these challenges. The platform replaces cumbersome, wired setups with discreet, wireless, wearable sensors that a patient can wear for weeks at a time while continuing their daily activities at home. This shift from a 72-hour hospital-based snapshot to a multi-week, real-world recording dramatically increases the probability of capturing the objective evidence needed for a diagnosis.

But the true strategic advantage lies in the integration of its AI platform, REMI Vigilenz™. Collecting weeks of continuous EEG data creates a new problem: a data deluge that would be overwhelming for clinicians to review manually. REMI Vigilenz™ AI analyzes the EEG stream, automatically flagging potential electrographic seizures for efficient review. This fusion of long-duration sensing with intelligent analysis makes the entire model scalable and clinically viable.

Critically, Epitel has secured five U.S. FDA 510(k) clearances, including a Predetermined Change Control Plan (PCCP) for its AI. This forward-thinking regulatory approval allows Epitel to continuously update and improve its AI algorithms based on new data without needing to return to the FDA for each iteration. This provides a powerful competitive moat, enabling the company to rapidly enhance its AI's accuracy and utility, staying ahead of competitors in a fast-evolving field. The platform’s clearance for patients as young as one year old further expands its addressable market to the most vulnerable populations.

The Investor Bet: Why Remote Brain Health is a Hot Market

This $26 million Series B, with repeat participation from its Series A investors, is a powerful vote of confidence not just in Epitel, but in the entire remote diagnostics market. Venture firms like Catalyst Health Ventures and Genoa Ventures are making a clear statement: the future of healthcare is decentralized, data-driven, and patient-centric. They see a massive market opportunity in disrupting legacy systems with technology that delivers better outcomes more efficiently.

“The ambulatory EEG market has needed this kind of disruption for decades, and Epitel has built the right solution at the right moment,” noted Joshua Phillips, Founder and Managing Partner at Catalyst Health Ventures. “This round gives the team the runway to move fast and meet the demand that's already there.”

His comment highlights a key strategic insight: the demand for better EEG monitoring isn't speculative; it's a long-standing, well-documented need. Epitel is not creating a market but is instead providing a technologically superior solution to an existing, underserved one. This reduces investment risk and provides a clear path to commercialization.

Navigating the Path to Market Dominance

With fresh capital, Epitel is executing a multi-pronged strategy to accelerate adoption. The funds will be used to scale its sales, marketing, and customer support teams, creating a robust commercial infrastructure. A key focus will be on streamlining deployment to help clinical teams integrate REMI into their existing workflows with minimal friction.

A significant barrier for new medical technologies is often reimbursement. Epitel has strategically navigated this by ensuring its system is reimbursable using pre-existing CPT codes. This removes a major hurdle for adoption, making the financial case for switching to REMI straightforward for hospitals and clinics.

While competitors exist, Epitel’s strategic positioning is strong. Companies like Ceribell focus on rapid, acute-care EEG in emergency settings, whereas traditional manufacturers like Nihon Kohden and Cadwell still largely operate in the wired-system paradigm. Epitel has carved out a distinct and valuable niche in long-term, ambulatory monitoring for diagnosis, a segment where its combination of a wireless form factor, extended wear time, and AI-powered analysis provides a compelling advantage.

By empowering non-specialists to apply the sensors and enabling remote neurologists to review AI-flagged data, Epitel is effectively unbundling neurological expertise from physical location. This model holds the potential to redefine the standard of care, making high-quality seizure diagnosis equitable and accessible for millions, regardless of where they live.